<DOC>
	<DOCNO>NCT02205411</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness ReliantHeart HeartAssist 5® VAD System patient listed heart transplantation risk death refractory end-stage heart failure .</brief_summary>
	<brief_title>Clinical Trial Evaluate ReliantHeart HeartAssist 5® VAD System Patients Awaiting Heart Transplantation</brief_title>
	<detailed_description>The HeartAssist 5® VAD System intend use bridge heart transplantation compare HeartMate II HVAD device . Patients meet study criterion randomize 1:1 either HeartAssist 5® VAD System ( treatment group ) control group ( HeartMate II HVAD ) . The physician option choose control device implant . The primary objective study show non-inferiority HeartAssist 5® ( treatment group ) control group .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Able sign Informed Consent . 2 . Age ≥ 18 3 . Body Surface Area ( BSA ) ≥ 1.2 m2 . 4 . Cardiac transplant candidate , define : Listed cardiac transplant , designate institution 's multidisciplinary transplant committee appropriate forLVAD BridgetoTransplantation therapy , Designated institution 's multidisciplinary transplant committee : 1 ) appropriate candidate LVAD Bridgeto transplant therapy , 2 ) An inappropriate candidate LVAD destination therapy 5 . LVAD implantation approve institution 's multidisciplinary transplant committee . 6 . Patient NYHA Class IV . 7 . Able return clinical site routine follow visit . 1 . Cardiothoracic surgery within 30 day prior enrollment . 2 . Acute Myocardial Infarction within 14 day prior enrollment . 3 . Prior cardiac transplantation , leave ventricular reduction surgery , cardiomyoplasty leave ventricular assist device . 4 . Mechanical , animal , human tissue heart valve . 5 . History untreated abdominal thoracic aortic aneurysm &gt; 5 cm . 6 . On ventilator support &gt; 72 hour within four day immediately prior enrollment . 7 . Ongoing mechanical circulatory support intraaortic balloon pump ( IABP ) . 8 . Proven history pulmonary embolism within 90 day enrollment . 9 . Moderate severe aortic insufficiency determine echocardiogram without plan correction pump implantation surgery . 10 . Requires aortic , mitral , tricuspid pulmonary valve replacement ( include Bioprosthetic valve ) leave ventricular ( LV ) aneurysm resection . 11 . Uncorrected thrombocytopenia generalize coagulopathy ( e.g. , platelet &lt; 100,000 , INR &gt; 1.6 PTT &gt; 2.5 time control absence anticoagulation therapy ) 12 . Severe right ventricular failure define anticipate need right ventricular assist device ( RVAD ) support OR extracorporeal membrane oxygenation ( ECMO ) time implantation OR right atrial pressure &gt; 20 mmHg multiple inotropes . 13 . Significant renal dysfunction define &gt; 3.5 mg/dl require hemo peritoneal dialysis renal failure ( exclude ultrafiltration fluid removal ) . 14 . Evidence intrinsic hepatic disease define liver enzyme value ( AST , ALT LDH &gt; 3 time upper limit normal ) OR total bilirubin &gt; 3 mg/dl OR biopsy proven liver cirrhosis portal hypertension . 15 . Pregnancy 16 . Active systemic infection prior study enrollment yet resolve treatment . Active Systemic Infection define one follow spite antibiotic , antiviral antifungal treatment : 2 consecutive positive culture ; elevate temperature &gt; 37.2 ( °C ) white blood cell count &gt; 11.0 ( 103/ml ) ; hypotension , tachycardia generalize malaise . 17 . Stroke within 90 day prior enrollment OR patient history cerebral vascular disease &gt; 80 % extra cranial stenosis document carotid Doppler study transplant evaluation 18 . Modified Rankin Scale score ≥ 2 neurologic disability confirm imaging ( CT MRI ) . 19 . Significant low extremity peripheral vascular disease accompany rest pain leg ulceration . 20 . Intolerant anticoagulant antiplatelet therapy peri postoperative therapy investigator may administer base upon patient 's health status . 21 . Psychiatric disorder , psychosocial behavior likely impair compliance study protocol . 22 . Receiving therapy investigational intervention participate clinical investigation time enrollment . 23 . Condition , heart failure , may limit survival less three ( 3 ) year and/or would exclude cardiac transplantation . 24 . Unwilling unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>heart assist device</keyword>
	<keyword>ventricular assist device</keyword>
</DOC>